352PEarly safety from a phase I, multicenter, open-label,...

352PEarly safety from a phase I, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL)

Yamazaki, N, Koga, H, Kojima, T, Tsutsumida, A, Namikawa, K, Yi, M, Mera, K, Pickett-Gies, C
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy439.007
Date:
November, 2018
File:
PDF, 79 KB
2018
Conversion to is in progress
Conversion to is failed